Effects of Dapagliflozin on Progression of Alport Syndrome

Status Recruiting

Clinical Trial Summary

Recently, a series of large clinical trials have confirmed the cardio-renal protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors. but few patients with hereditary nephritis were included in these studies. This study is to evaluate the effects of dapagliflozin on slowing kidney disease progression in patients with Alport syndrome.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06226896
Study type	Observational
Source	Nanjing University School of Medicine
Contact	Qiong Wu
Phone	+8680863234
Email	wuqiong80863234@163.com
Status	Recruiting
Phase
Start date	November 15, 2023
Completion date	September 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01696253` - Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
Terminated	`NCT01602835` - Human Urine Sample Collection for Alport Nephropathy Biomarker Studies	N/A
Recruiting	`NCT00481130` - Alport Syndrome Treatments and Outcomes Registry
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Recruiting	`NCT05448755` - A Study of ELX-02 in Patients With Alport Syndrome	Phase 2
Recruiting	`NCT06274489` - A Study to Evaluate Setanaxib in Patients With Alport Syndrome	Phase 1/Phase 2
Terminated	`NCT02855268` - Study of Lademirsen (SAR339375) in Patients With Alport Syndrome	Phase 2
Recruiting	`NCT05927467` - Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)
Terminated	`NCT03749447` - An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)	Phase 3
Completed	`NCT03019185` - A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL	Phase 2/Phase 3
Completed	`NCT01705132` - Urinary Biomarkers of the Progression of Alport Kidney Disease	N/A
Recruiting	`NCT05267262` - Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis	Phase 2
Completed	`NCT00622544` - A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
Recruiting	`NCT02378805` - European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
Not yet recruiting	`NCT05655728` - Treatment With Metformin in Chinese Children With Alport Syndrome	Phase 4
Completed	`NCT00309257` - Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome	Phase 2
Not yet recruiting	`NCT05133050` - Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants	N/A
Recruiting	`NCT04947813` - Genotype-Phenotype Correlations in Patients With Alport Syndrome
Active, not recruiting	`NCT04573920` - Atrasentan in Patients With Proteinuric Glomerular Diseases	Phase 2